Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2008
10/22/2008CN101288705A Medicine composition mainly for adjusting blood fat and its preparation method
10/22/2008CN101288698A Medicinal composition for preventing birth defect and improving memory
10/22/2008CN101288697A Medicinal composition for reducing fat, blood pressure, blood sugar, cholesterin and blood fat
10/22/2008CN101288691A Chinese medicinal extracts for treating í«two high, one lowí», capsules and preparation method thereof
10/22/2008CN101288641A Coenzyme Q10 water dispersion and preparation method thereof
10/22/2008CN101288465A Mushroom oral liquid
10/22/2008CN101288424A Lotus leaf instant milky tea
10/22/2008CN100427486C Novel benzimidazole derivatives
10/22/2008CN100427143C Solid preparation
10/22/2008CN100427111C Hemp seed oil soft capsule preparation and its production method
10/22/2008CN100427103C Activity combination of marine life and application
10/22/2008CN100427093C 4(2-butylamino)-2,7-dimethyl-8-(2-methyl(-6-methoxyp-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine as corticotropin releasing factor receptor
10/21/2008US7439356 Substituted indan derivatives
10/21/2008US7439335 Synthetic antigen presenting matrix/biological scaffold comprising immobilized major histocompatibility complex for use in identifying modulator for treatment and prevention of autoimmune, allergy and cancer disorders
10/21/2008US7439263 e.g. 1-({[9-(hydroxymethyl)-3-oxaspiro[5.5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile; dipeptidyl-peptidase IV inhibitor; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity
10/21/2008US7439251 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
10/21/2008US7439248 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or salt; compressed tablets; microcrystalline cellulose, magnesium stearate, lactose, or talc excipients; antidiabetic agents for non-insulin dependent diabetes; insulin sensitizers
10/21/2008US7439244 e.g. 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline; serotonin receptor modulator; antidepressant, anxiolytic agent, cognition activator; schizophrenia, obesity, Alzheimer's disease
10/21/2008US7439242 PPARγ modulators
10/21/2008US7439236 Pharmaceutical composition for the treatment of CNS and other disorders
10/21/2008US7438911 Antibody against human insulin-like growth factor
10/21/2008US7438902 treating diabetes mellitus; isolating a nestin-positive pancreatic stem cell from a pancreatic islet of a donor; transferring the stem cell into the patient, wherein it differentiates into an insulin-producing cell; across allogeneic or xenogeneic barriers and graft rejection does not occur
10/21/2008CA2468847C Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
10/21/2008CA2444587C Pharmaceutical compositions of low salt polyallylamine hydrochloride
10/21/2008CA2438294C Pyridopyrimidine or naphthyridine derivative
10/21/2008CA2331408C Fatty analogues for the treatment of obesity, hypertension and fatty liver
10/21/2008CA2296732C Polyhydroxyalkylpyrazine derivatives, their preparation and medicines containing them
10/21/2008CA2270893C N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity
10/20/2008CA2629419A1 Dietary supplement for the compensation of nutritional deficiency
10/16/2008WO2008124522A2 Amylin formulations
10/16/2008WO2008123891A1 PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
10/16/2008WO2008123821A1 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
10/16/2008WO2008123625A1 Method for activating receptor by cofactor and method for utilizing ligand activity
10/16/2008WO2008123469A1 Six-membered amide compound and use thereof
10/16/2008WO2008123417A1 Anti-fatigue agent
10/16/2008WO2008123298A1 Infusion preparation for cancer patient
10/16/2008WO2008123207A1 Ornithine derivative
10/16/2008WO2008123128A1 Adiponectin production enhancer
10/16/2008WO2008123093A1 Agent for prevention or treatment of iron overload
10/16/2008WO2008122810A1 Phthalazinone derivatives and their use as medicament to treat cancer
10/16/2008WO2008122667A2 Ureylene derivatives
10/16/2008WO2008122618A1 Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
10/16/2008WO2008122352A1 Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
10/16/2008WO2008122174A1 A chinese medicine preparation for treating and preventing diabetes and its complication, improving immunity and process thereof
10/16/2008WO2008064615A3 Crystalline and amorphous forms of rimonabant and processes for obtaining them
10/16/2008WO2008058995A3 Use of cytohesin inhibitors for chemically inducing longevity
10/16/2008WO2008054211A9 Nutritional products comprising saccharide oligomers
10/16/2008WO2008054208A3 Use of nutritional compositions for preventing disorders
10/16/2008US20080255499 Using alpha ketoamino acid; tissue toxicity; urogenital disorders
10/16/2008US20080255240 Obesity; dietetics; hypotensive agents; antidiabetic agents; dyslipidemia; cardiovascular disorders; osteoarthritis; gall bladder disease; endometrosis; anticancer agents; vascular system disorders; apoptosis
10/16/2008US20080255225 Botanical Extract Composition
10/16/2008US20080255218 N-benzylamino cyclic thioureas; obesity and related disorders; (N-(3-{(4S)-1-[(1S)-2-(benzylamino)-1-methylethyl]-3-[2-(3-fluorophenyl)ethyl]-2-thioxoimidazolidin-4-yl}propyl)guanidine
10/16/2008US20080255216 Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
10/16/2008US20080255212 disorders of lipid and/or carbohydrate metabolism, metabolic disorders, central nervous system disorders; 3-{2-Chloro-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-ylmethoxy]-phenyl}-4H-[1,2,4]oxadiazole-5-one
10/16/2008US20080255211 cannabinoid receptors modulators; metabolic syndrome, obesity, hyperlipidemia, type II diabetes, atherosclerosis, substance addiction, liver cirrhosis, schizophrenia, sexual dysfunction, anxiety; 5-(5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-3-tert-butyl-1,2,4-oxadiazole
10/16/2008US20080255209 Combination of a NSAID and a PDE-4 inhibitor
10/16/2008US20080255206 Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases
10/16/2008US20080255201 Ppar active compounds
10/16/2008US20080255191 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/16/2008US20080255162 Treating diseases mediated by phosphatidyl inositol 3-kinase; cardiovascular disorders; anticarcinogenic, antiarthritic, anticoagulant, antiinflammatory, antiischemic,and hypotensive agents; chronic obstructive pulmonary disease; autoimmune diseases; diabetes, atherosclerosis, bronchitis, strokes
10/16/2008US20080255159 Arthritis, obesity, (non-insulin dependent) diabetes calcitonin-induced osteoporosis; administering allograft transplantation; dipeptidyl peptidase-IV (DPP-IV) inhibitors
10/16/2008US20080255154 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes
10/16/2008US20080255152 Diaryl ethers as opioid receptor antagonists
10/16/2008US20080255141 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders
10/16/2008US20080255137 N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto
10/16/2008US20080255129 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
10/16/2008US20080255128 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis
10/16/2008US20080255126 Inhibitors of post-proline cleaving proteases
10/16/2008US20080255121 Combination Drug for Treating Autoimmune Disease
10/16/2008US20080255114 2-aminobenzoxazole carboxamides as 5ht3 modulators
10/16/2008US20080255110 Imidazoquinoline derivatives as adenosine a3 receptor ligands
10/16/2008US20080255108 Novel thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
10/16/2008US20080255106 N-(3-Methoxypropyl)-2-[2-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridine-7-carboxamide hydrochloride; antidepressant, analgesic, anxiolytic agent; amyotrophic lateral sclerosis, Down syndrome, Huntington's Disease, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorder
10/16/2008US20080255093 Compositions and methods for treating obesity and related disorders
10/16/2008US20080255084 Combination of Organic Compounds
10/16/2008US20080255083 New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds
10/16/2008US20080255078 Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; carboxy or hydroxyalkoxyalkoxy-group-substituted phenyl at position 2 of 1,1,2-triphenylethylene compounds
10/16/2008US20080255068 Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis
10/16/2008US20080255064 Biological assay; experimental reporter expression vector has cholecystokinin promoter upregulating agent operably linked to experimental Renilla luciferase reporter gene; separately detectable; co-transform experimental vector and control vector in pancreatic islet host cells; increase plasma insulin
10/16/2008US20080255050 Administering 2-aminopurine or a pharmaceutically salt thereof; optionally also administering an additional hypolipidemic agent; 2-AP and nonphosphorylatable eIF-2 alpha mutant inhibit eIF-2 alpha phosphorylation, inhibit foam cell formation and atherosclerosis development
10/16/2008US20080255046 Y2 Selective Receptor Agonists for Therapeutic Interventions
10/16/2008US20080255042 CaSR Antagonist
10/16/2008US20080255031 Method for enhancing insulin secretion
10/16/2008US20080255030 Compositions and methods for the modulation of jnk proteins
10/16/2008US20080254155 Modulating gene expressions of key enzymes associated with cholesterol metabolism in vivo; natural source; anticholesterol agents
10/16/2008US20080254153 Water Dispersible Composition and Method for Preparing Same
10/16/2008US20080254135 Resveratrol-containing compositions for general health and vitality
10/16/2008US20080254127 Inhalation particles incorporating a combination of two or more active ingredients
10/16/2008US20080254100 Producing blunted postprandial glycemic response; using nutritional meal replacements that are rapidly metabolized and absorbed in small intestine; reducing body weight
10/16/2008US20080254099 Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease
10/16/2008US20080254090 Porcine Islets Cultured With Porcine Sertoli Cells For Xenotransplantation
10/16/2008US20080254087 Methods For Administering Hypoglycemic Agents
10/16/2008US20080254028 Caspase-8 interacting polypeptide (Cari) for use in identifying modulators for prevention and treatment of autoimmune, inflammatory, connective tissue and liver disorders
10/16/2008CA2683682A1 Phthalazinone derivatives and their use as medicament to treat cancer
10/16/2008CA2682875A1 Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
10/16/2008CA2681861A1 Ornithine derivative
10/16/2008CA2681560A1 Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
10/15/2008EP1980560A2 C-glycoside derivatives for the treatment of diabetes
10/15/2008EP1980249A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
10/15/2008EP1980247A1 Growth hormone secretion regulator
1 ... 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 ... 1298